Enclomiphene Citrate for Post-Cycle Therapy (PCT): Evidence, Dosage, and Protocol

Clinical Evidence: Enclomiphene for Testosterone Restoration

Enclomiphene is the trans-isomer of clomiphene (compared to the cis-isomer, zuclomiphene). Commercial Clomid (clomiphene citrate) contains approximately 62% enclomiphene and 38% zuclomiphene. Research has established that enclomiphene is responsible for virtually all of clomiphene’s SERM-mediated LH/FSH stimulation, while zuclomiphene is a weaker estrogen agonist responsible for many of the mood and libido side effects.

The pivotal clinical trials establishing enclomiphene’s efficacy were conducted by Repros Therapeutics. Kim et al. (2013) conducted a Phase II randomized controlled trial in 124 hypogonadal men comparing enclomiphene 6.25 mg/day, 12.5 mg/day, 25 mg/day, and placebo. All three active doses produced significant and dose-dependent increases in testosterone and LH/FSH within 30 days (Kim et al., 2013, doi:https://pubmed.ncbi.nlm.nih.gov/26496621/).

Wiehle et al. (2014) published a Phase III double-blind trial comparing enclomiphene citrate 12.5 mg/day and 25 mg/day to testosterone gel in 200 hypogonadal men over 3 months. Enclomiphene normalized testosterone in 77% of subjects (25 mg arm) compared to 81% for testosterone gel, nearly identical efficacy, but while testosterone gel suppressed LH and spermatogenesis, enclomiphene maintained or increased both. This is the critical differentiator for PCT use: enclomiphene restores the axis without the testicular atrophy caused by exogenous testosterone (Wiehle et al., 2014, doi:10.1111/andr.12150).

Drobnis et al. (2017) confirmed that enclomiphene maintained sperm counts and testicular volume throughout treatment while increasing testosterone to normal range in all subjects, a combination that no form of testosterone replacement therapy can achieve.

Mechanism: How Enclomiphene Restores the HPG Axis

Enclomiphene’s mechanism is fundamentally the same as clomiphene, hypothalamic estrogen receptor blockade, but cleaner due to the absence of zuclomiphene’s estrogenic interference.

Hypothalamic ER Blockade and GnRH Pulse Restoration

During an anabolic steroid cycle, elevated androgens suppress GnRH pulsatility via hypothalamic negative feedback (largely mediated by aromatization to estrogen). Enclomiphene binds competitively to hypothalamic estrogen receptors and acts as an antagonist, blocking estrogen’s inhibitory signal. The hypothalamus, perceiving inadequate estrogen feedback, increases GnRH pulse frequency and amplitude.

Pituitary LH and FSH Secretion

Restored GnRH pulsatility drives the pituitary to increase LH and FSH secretion. LH directly stimulates Leydig cell testosterone synthesis. FSH stimulates Sertoli cells supporting spermatogenesis. The net result is increased endogenous testosterone and preserved/restored spermatogenesis, the exact recovery profile needed after a suppressive anabolic cycle.

Why Enclomiphene May Be Superior to Clomid for PCT

The zuclomiphene component of commercial Clomid has a biological half-life of approximately 30 days compared to enclomiphene’s 10-hour half-life. Zuclomiphene accumulates with repeated dosing and exerts partial estrogenic agonism in some tissues, which can reduce SHBG slightly while causing mood instability and reduced libido in sensitive users. Enclomiphene’s rapid clearance means each dose produces a clean, transient antagonist pulse without accumulation or estrogenic carry-over.

Enclomiphene PCT Protocol

Based on clinical trial data and established practice:

• Timing: Begin 14 to 21 days after last anabolic steroid injection (long esters), or 3 to 5 days after last oral steroid dose
• Standard dose: 12.5 to 25 mg/day for 6 to 8 weeks
• Lower-dose option: 12.5 mg/day produces significant testosterone restoration with minimal side effects (equivalent to the 12.5 mg arm in Kim et al., 2013)
• Combination approach: Some users combine enclomiphene 12.5 mg/day with Nolvadex 10-20 mg/day for additive HPG stimulation

Monitoring: Bloodwork at 4 weeks (LH, FSH, total testosterone, estradiol) is recommended to confirm axis recovery and adjust dose if needed. Full recovery is typically confirmed 4 to 6 weeks post-PCT completion.

Enclomiphene vs Clomid for PCT: Head-to-Head Comparison

Factor	Enclomiphene	Clomid (racemic)
LH/FSH stimulation	Strong (primary active isomer)	Strong
Testosterone increase	Equivalent at 12.5-25 mg/day	Equivalent at 25-50 mg/day
Mood side effects	Lower (no zuclomiphene accumulation)	Higher in sensitive users
Libido impact	Generally neutral to positive	Variable, can reduce in some users
Visual side effects	Much rarer	Rare but documented
Clinical trial data	Phase II/III RCTs	Decades of clinical data
Availability	Research compound	Research compound / prescription

Side Effects and Safety

Enclomiphene is well-tolerated in clinical trials. At 12.5-25 mg/day:

• Hot flashes: Reported in ~10-15% of subjects (result of hypothalamic ER blockade, expected mechanism-based effect)
• Headache: Mild, transient, more common in the first week
• Visual disturbances: Rare (much less frequent than with racemic clomiphene; primarily attributable to the zuclomiphene component that enclomiphene lacks)
• Mood changes: Minimal compared to racemic clomiphene

No serious adverse events were attributable to enclomiphene in Phase II/III trials at these doses. Sperm counts and testicular volume were maintained throughout treatment, an advantage over all exogenous testosterone products.

Frequently Asked Questions

Is enclomiphene better than Clomid for PCT?

For users who tolerate standard Clomid well, the practical difference is modest. For users who experience mood instability, reduced libido, or visual disturbances on racemic clomiphene, enclomiphene offers equivalent testosterone restoration with superior tolerability, because the zuclomiphene component responsible for those side effects is absent.

What dose of enclomiphene is equivalent to 50 mg Clomid?

Based on isomer composition (Clomid is ~62% enclomiphene), 50 mg Clomid contains approximately 31 mg enclomiphene. However, enclomiphene is dosed lower in clinical trials (12.5-25 mg/day) and produces equivalent LH/FSH responses to 50 mg Clomid in direct comparisons. The 25 mg/day enclomiphene dose is typically considered comparable to 50 mg/day Clomid in terms of testosterone restoration outcomes.

How long does enclomiphene PCT take?

Clinical trials demonstrate testosterone normalization within 4 to 8 weeks. Most users follow a 6 to 8 week protocol. Bloodwork should be done 4 weeks post-PCT to confirm full axis recovery. If LH and testosterone remain suboptimal at this point, extending PCT by 2 to 4 weeks or adding a second SERM is common practice.

How to Source Enclomiphene in Canada

Elite Bio Supply carries pharmaceutical-grade Enclomiphene Citrate with domestic shipping across Canada via Canada Post. All batches are third-party tested for purity and identity. View Enclomiphene product page and order.

Related Guides

• Enclomiphene Dosage Guide
• Enclomiphene Side Effects
• Buy Enclomiphene in Canada
• Clomid for PCT: The Standard SERM Protocol
• Enclomiphene for Secondary Hypogonadism